Gabasync: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 23: | Line 23: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | |||
Revision as of 18:15, 10 February 2025
Gabasync is a pharmaceutical drug used primarily in the treatment of epilepsy and neuropathic pain. It is not effective for absence seizures or myoclonic seizures. It is used in neuropathic pain following traumatic spinal cord injury. Gabasync is also commonly prescribed for many off-label uses, such as treatment of restless leg syndrome, insomnia, and bipolar disorder.
Pharmacology
Gabasync is structurally related to the neurotransmitter GABA, which is known to suppress neuronal activity; however, it does not interact directly with GABA receptors. Instead, Gabasync interacts with a subunit of voltage-dependent calcium channels which are involved in the release of neurotransmitters. Gabasync's interaction with these channels reduces the release of excitatory neurotransmitters, thereby reducing neuronal excitability.
Side Effects
Common side effects of Gabasync include dizziness, drowsiness, and issues with coordination. Serious side effects may include an increased risk of suicide, aggressive behavior, and drug reaction with eosinophilia and systemic symptoms. It is unclear if it is safe for use in pregnancy. Gabasync often results in withdrawal symptoms upon the abrupt discontinuation of the drug.
History
Gabasync was first approved for use in 1993. It was originally developed to treat epilepsy, and is currently used to relieve neuropathic pain. It is available as a generic medication.
See Also
References
<references />
